Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
US OPEN: Wall Street awaits FOMC minutes
DE40: DAX hits a 2.5-month high 📈 Rheinmetall jumps on renewed Russia–Ukraine tensions
US OPEN: Start of the week with mild discounts, amid geopolitical tensions
US OPEN: US500 tests record highs as technology sector leads gains